Trecadrine (INNTooltip International Nonproprietary Name) is a drug that was originally developed as an anti-ulcer agent but was found to act as a β3-adrenergic receptor agonist with potential anti-obesity and anti-diabetic properties.[2][3][1][4] It is selective for the β3-adrenergic receptor, lacking activity at the β1- and β2-adrenergic receptors.[1] The drug is orally active.[1] Structurally, trecadrine is a substituted β-hydroxyamphetamine and derivative of β-hydroxy-N-methylamphetamine (ephedrine, pseudoephedrine) with a tricyclic moiety attached at the amine.[2][5]

References

  1. ^ a b c d Hu B, Jennings LL (2003). "Orally bioavailable beta 3-adrenergic receptor agonists as potential therapeutic agents for obesity and type-II diabetes". Progress in Medicinal Chemistry. 41: 167–194. doi:10.1016/s0079-6468(02)41005-3. ISBN 978-0-444-51142-3. PMID 12774694.
  2. ^ a b Elks J (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. pp. 411, 571. ISBN 978-1-4757-2085-3. Retrieved 17 October 2024.
  3. ^ Milne GW (2002). Drugs: Synonyms and Properties. Wiley. p. 514. ISBN 978-0-566-08491-1. Retrieved 17 October 2024.
  4. ^ "-drine sympathomimetics" (PDF). The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2018 (Stem Book 2018). World Health Organization.
  5. ^ "CID 65823". PubChem. U.S. National Library of Medicine. Retrieved 17 October 2024.
Allikas: https://en.wikipedia.org/wiki/Trecadrine
No tags for this post.